Smith & Nephew SNATS (NYSE:SNN) Stock Rating Upgraded by Wall Street Zen

Smith & Nephew SNATS logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Smith & Nephew SNATS from “hold” to “buy.” Other analyst views remain mixed, and MarketBeat’s consensus rating is “Reduce,” with an average price target of $31.91.
  • Shares rose 0.8% to $31.23 in Friday midday trading. The stock’s 50-day moving average was $28.73, compared with its 200-day average of $30.99.
  • Institutional investors own 25.64% of the company’s shares; several major investors, including BlackRock, reported new positions in the second quarter.
  • Interested in Smith & Nephew SNATS? Here are five stocks we like better.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Sunday, Wall Street Zen reports.

Several other analysts have also issued reports on the company. Zacks Research lowered Smith & Nephew SNATS from a "hold" rating to a "strong sell" rating in a report on Thursday, November 5th. Morgan Stanley downgraded Smith & Nephew SNATS from an "overweight" rating to an "equal weight" rating in a research note on Wednesday, September 2nd. Weiss Ratings lowered Smith & Nephew SNATS from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, September 24th. Berenberg Bank set a $33.88 price objective on Smith & Nephew SNATS in a research note on Friday, September 11th. Finally, Bank of America cut Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research note on Tuesday, September 8th. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Reduce" and a consensus target price of $31.91.

View Our Latest Stock Analysis on Smith & Nephew SNATS

Smith & Nephew SNATS Trading Up 0.8%

Shares of SNN traded up $0.23 during midday trading on Friday, hitting $31.23. The stock had a trading volume of 1,365,146 shares, compared to its average volume of 1,525,150. The company has a 50 day simple moving average of $28.73 and a two-hundred day simple moving average of $30.99. Smith & Nephew SNATS has a twelve month low of $26.12 and a twelve month high of $37.09. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14.

Institutional Investors Weigh In On Smith & Nephew SNATS

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Smith & Nephew SNATS during the second quarter worth $505,323,000. Bank of America Corp DE bought a new stake in Smith & Nephew SNATS in the second quarter worth about $97,223,000. Bank of New York Mellon Corp bought a new stake in shares of Smith & Nephew SNATS in the 2nd quarter worth approximately $89,325,000. Caisse de depot et placement du Quebec purchased a new position in shares of Smith & Nephew SNATS during the 2nd quarter valued at $64,186,000. Finally, Legal & General Group Plc purchased a new stake in Smith & Nephew SNATS during the second quarter valued at about $35,338,000. Institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Company Profile

(Get Free Report)

Smith & Nephew plc is a global medical technology company that develops and sells products used in surgery, orthopaedics and wound care. Its offerings include implants for hip and knee replacement, instruments and devices for sports medicine and ear, nose and throat procedures, and products designed to manage wounds and support tissue repair. Founded in 1856 in Hull, England, the company began as a pharmacy business before expanding into medical products. It now serves healthcare providers and patients in markets around the world.

Read More

Analyst Recommendations for Smith & Nephew SNATS (NYSE:SNN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Smith & Nephew SNATS Right Now?

Before you consider Smith & Nephew SNATS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.

While Smith & Nephew SNATS currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines